Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piro Lito

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Nature|November 11, 2021
Diverse alterations associated with resistance to KRAS(G12C) inhibitionYulei Zhao, Yonina R Murciano-Goroff, Jenny Y Xue, et al.
Science (New York, N.Y.)|August 17, 2023
Chemical remodeling of a cellular chaperone to target the active state of mutant KRASChristopher J Schulze, Kyle J Seamon, Yulei Zhao, et al.
Cancer Discovery|October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsJill Hallin, Lars D Engstrom, Lauren Hargis, et al.
The New England Journal of Medicine|September 21, 2020
KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.
The New England Journal of Medicine|June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in CancerMark M Awad, Shengwu Liu, Igor I Rybkin, et al.
Nature|April 8, 2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Bianca J Lee, Jingjing Jiang, et al.
Nature Medicine|November 10, 2022
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancerJustin Jee, Emily S Lebow, Randy Yeh, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Nature|November 11, 2021
Diverse alterations associated with resistance to KRAS(G12C) inhibitionYulei Zhao, Yonina R Murciano-Goroff, Jenny Y Xue, et al.
Science (New York, N.Y.)|August 17, 2023
Chemical remodeling of a cellular chaperone to target the active state of mutant KRASChristopher J Schulze, Kyle J Seamon, Yulei Zhao, et al.
Cancer Discovery|October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and PatientsJill Hallin, Lars D Engstrom, Lauren Hargis, et al.
The New England Journal of Medicine|September 21, 2020
KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.
The New England Journal of Medicine|June 23, 2021
Acquired Resistance to KRAS<sup>G12C</sup> Inhibition in CancerMark M Awad, Shengwu Liu, Igor I Rybkin, et al.
Nature|April 8, 2024
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapyMatthew Holderfield, Bianca J Lee, Jingjing Jiang, et al.
Nature Medicine|November 10, 2022
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancerJustin Jee, Emily S Lebow, Randy Yeh, et al.
Pageof 5